Hydrix Limited reports back-to-back profitable quarters driven by strong margins and cost efficiencies, underpinned by a robust $40 million sales opportunity pipeline in cardiac and medtech sectors.
HITIQ Limited has received $1.6 million from the R&D Tax Incentive Scheme, using most of it to repay its RDTI Facility with Keystone Capital Partners, signaling a strategic move to streamline its R&D funding.